CovaLys

CovaLys is an innovative orally active covalent pan-IAP inhibitor of oncogenic Inhibitor of Apoptosis Proteins (IAPs)

CovaLys can be developed as a single agent therapeutic or as a chemosensitizer in tumors that develop resistance to chemotherapy, radiation, or immunotherapy.

Stage: late pre-clinical.